Preclinical Testing News and Research

RSS

Potential new way to fight HIV

Researchers have confirmed for the first time the benefit of an innate defense system present in the few patients who remain healthy after years of infection with HIV despite receiving no treatment, according to an article published in the September edition of the Journal of Virology.

1 Sep 2005

Promising new tuberculosis drug enters clinical trial

A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced this week.

15 Jun 2005

Guidelines for research involving human embryonic stem cells

The National Academies today recommended guidelines for research involving human embryonic stem cells, and urged all institutions conducting such research to establish oversight committees to ensure that the new guidelines will be followed.

26 Apr 2005

Australian biotech, Bionomics acquires central nervous system (CNS) business

Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.

6 Mar 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004

Genetically engineered viruses may create new class of cancer therapies

A genetically engineered virus can selectively kill cancerous cells in the lung and colon while leaving healthy cells intact, according to new research published today in Cancer Research by William Wold and colleagues at Saint Louis University School of Medicine.

15 May 2004

SARS antibody sent to China

Responding to a request from a Chinese biotechnology company working closely with officials in China, Medarex, Inc. and the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) have shipped to Beijing a sample of the fully human antibody to SARS developed by Medarex and MBL/UMMS.

26 Apr 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004